Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival

International Journal of Urology

Volumn 16, Issue 9, 2009, Pages 726-731

  Nayyar, Rishi ^a   Sharma, Nitin ^a   Gupta, Narmada P ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory; Prostate cancer; Zoledronic acid

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; FOSFESTROL; GONADORELIN AGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GLEASON SCORE; HAIR LOSS; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; KAPLAN MEIER METHOD; LIVER TOXICITY; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; RASH; SIDE EFFECT; SKIN PIGMENTATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIDAZOLES; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 70349251713     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02351.x     Document Type: Article

References (20)

1. Jemal A, Siegel R, Hao Y et al. Cancer statistics. CA Cancer J. Clin. 2008 58 : 71 96.
2. Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer J. Clin. 1972 22 : 232 240.
3. Tannock IF, Wit RD, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004 351 : 1502 1512.
4. Petrylak DP, Tangen CM, Maha PH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 1520.
5. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen independent hormone refractory prostate cancer. Clin. Cancer Res. 2004 10 : 8147 8151.
6. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006 6 : 15.
7. Ullen A, Lennartsson L, Harmenberg U et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol. 2005 44 : 644 650.
8. Ural AU, Avcu F. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta Oncol. 2006 45 : 491 492.
9. Green JR. Bisphosphonates in cancer therapy. Curr. Opin. Oncol. 2002 14 : 609 615.
10. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J. Clin. 2005 55 : 300 318.
11. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997 50 : 920 928.
12. Petrylak DP, Caroline SJ, Catherine MT et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006 98 : 516 521.
13. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002 94 : 1458 1468.
14. Mason MD, Sydes MR, Glaholm J et al. A double blind, placebo controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl. Cancer Inst. 2003 95 : 1300 1311.
15. Parker CC. The role of bisphosphonates in treatment of prostate cancer. BJU Int. 2005 95 : 935 938.
16. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberg MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002 94 : 1457 1465.
17. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone refractory prostate cancer: preliminary results. Semin Oncol. 1999 26 : 14 18.
18. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 1999 17 : 958 967.
19. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol. 2001 19 : 2509 2516.
20. Vordos D, Paule B, Vacherot F et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2004 94 : 524 527.